BRIEF—Glenmark and Harbour BioMed agree deal over oncology candidate

Glenmark Pharmaceuticals and Harbour BioMed have entered into a license agreement for the Greater China territory to develop, manufacture and commercialize lead I-O candidate GBR 1302.

GBR 1302 is a bispecific antibody, developed by Glenmark, which targets both HER2 and CD3 for the treatment of HER2-positive cancers.

Noting that “the predominance of certain HER-2 positive cancers presents a significant clinical need,” in the area, Glenmark managing director Glenn Saldanha said “the opportunity to work collaboratively with Harbour BioMed on this program, which brings extensive local experience, is very important to Glenmark."